QIAGEN Strengthens QIAstat-Dx With New Barcelona Site to Drive Growth in Infectious Diseases and Precision Medicine Testing
1. QIAGEN plans new QIAstat-Dx site in Esplugues de Llobregat, opening 2026. 2. The site will enhance R&D in diagnostics for infectious and chronic diseases. 3. Partnerships with Eli Lilly and AstraZeneca will expand QIAstat-Dx applications. 4. The facility emphasizes rapid diagnostics, crucial for diverse healthcare needs. 5. LEED Platinum certification highlights commitment to energy-efficient building design.